More recently, maintenance with the anti-PD-L1 agent durvalumab after chemo-radiation for unresectable, locally advanced NSCLC, resulted in a significant improvement in terms of progression-free survival and overall survival (8). This evidence concerns the gene CD274 and non-small cell lung carcinoma.